 VALENCIA, Calif. and MELBOURNE, Australia, Feb. 24, 2021 GLOBE NEWSWIRE -- AVITA Medical, Inc. Nasdaq: RCEL; ASX: AVH AVITA Medical, a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced that it has commenced an underwritten registered public offering of its common stock. In addition, AVITA Medical is expected to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of its common stock sold in the offering on the same terms and conditions. All of the shares of common stock to be sold in the proposed offering will be offered by AVITA Medical. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 